Pfizer Inc., and Warner-Lambert Company

Last Updated:
In the Matter of Pfizer Inc., and Warner-Lambert Company
FTC Matter/File Number:


Docket Number:


Enforcement Type:

Part 2 Consents

Case Summary

Final consent order permits Pfizer’s merger with Warner-Lambert Company and requires divestitures in several pharmaceutical markets including: Pfizer’s RID brand of head lice treatment; Pfizer’s antidepressant drug, Celexa; Warner’s Cognex, a drug used in the treatment of Alzheimer’s disease; and assets relating to the Epidermal Growth Factor receptor tryosine kinase inhibitor - drugs under development to treat solid cancerous tumors such as head and neck, non-small cell lung, breast, ovarian, pancreas and colorectal cancers.